- Castor’s DCT platform helping medical device trials achieve compliance with patient-focused technology
- Driving innovation for medical device clinical trials, working with over 150 medical device companies
HOBOKEN, N.J. – November 1, 2021 – Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced the acceleration of medical device research & development with its decentralized clinical trial platform to power medical device studies globally. By working with over 150 medical device companies, Castor’s DCT platform is increasing the efficiency of launching medical device clinical trials by ensuring regulatory compliance, optimizing the patient experience, and streamlining the real-time collection of research data.
Innovation within the healthcare industry is on the rise, with medical device manufacturers uniquely positioned to make a global impact on the treatment and prevention of diseases. In line with market growth, the medical device landscape is increasingly complex, as global regulatory bodies enforce stricter regulatory standards for medical device trials.
For manufacturers, new regulations such as MDR-IVDR and the FDA 21st Century Cures Act are changing the path to approval and placing a greater emphasis on data quality, safety, and transparency. Leveraging Castor’s globally compliant platform, manufacturers can successfully navigate the regulatory landscape and ensure compliance with an easy-to-use, intuitive technology designed to optimize patient engagement and streamline data collection from multiple sources.
“Castor offers a truly seamless clinical trial experience for investigators and patients,” said Fernando Correia, MD Ph.D., Chief Medical Officer of Sword Health, a digital musculoskeletal (MSK) care provider. “Fast deployment was critical for us. Castor technology was easy to use and the self-service capability allowed us to deploy a study in just a few weeks. When it came time for our next study, we were able to cut the build time in half by reusing previous study builds.”
Castor’s modern interface and integration capabilities enable medical device manufacturers to achieve compliance and focus on patient outcomes, minimizing the burden of managing multiple technologies, vendors, and processes. Built for single and multi-site medical device clinical trials, Castor’s modular DCT platform can:
- Increase patient access to research and diversify the participant pool by automating the recruitment and enrollment process
- Optimize in-trial patient experience through streamlined workflows for data collection and engagement
- Simplify data collection from multiple sources such as ePRO/eCOA, wearables, biosensors, and EHR with Castor’s innovative open API
“For us, it’s important that digital technology is accessible and easy-to-use for patients and researchers. That’s why we are so passionate about delivering a complete self-service solution to help medical device manufacturers navigate their trials,” said Derk Arts, Ph.D., M.D., CEO and Founder of Castor. “We are excited by the opportunity to help medical device companies develop high-engagement, patient-friendly and data integrated clinical workflows that streamline the approval process and ultimately deliver the best products to market.”
The future of clinical trials is here. Learn more about how you can use Castor’s integrated platform in your next medical device trial at castoredc.com.
Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com. Follow us on Twitter at @castor.